Wolfe Research Initiates Coverage On Roivant Sciences with Outperform Rating, Announces Price Target of $17
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research analyst Andy Chen initiates coverage on Roivant Sciences (NASDAQ:ROIV) with an Outperform rating and a price target of $17.
February 15, 2024 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wolfe Research has initiated coverage on Roivant Sciences with an Outperform rating and set a price target of $17.
Analyst ratings, especially those with an Outperform status, can significantly influence investor sentiment and stock prices in the short term. The setting of a price target above the current trading price usually indicates an expectation of the stock's future appreciation, potentially leading to increased investor interest and a rise in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100